News & Updates

In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.

Neoadjuvant chemohormonal therapy (NCHT) plus radical prostatectomy (RP) confers significant biochemical progression-free survival (bPFS) benefits relative to neoadjuvant hormonal therapy (NHT) plus RP on patients with high-risk, locally advanced prostate cancer, reports a study.

Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.